The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
6
500 mg oral suspension
Celerion
Lincoln, Nebraska, United States
Changes in the varespladib blood levels and radioactivity in blood, urine and fecal samples
Time frame: 1 hour prior to drug, and post dose: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, and 120 hours after drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.